GENinCode Plc (LSE:GENI) entered a collaboration with Sohin Genetics to distribute its CARDIO inCode-Score test in Mexico.
The agreement covers commercial promotion and delivery of the polygenic risk score test for coronary heart disease prevention.
Mexico-based Sohin Genetics, a private healthcare company that provides integrated services, particularly in diagnostics and precision medicine, will market the test across its network of hospitals and clinics, providing training, sample handling and ordering through GENinCode’s SITAB international reporting system.
The collaboration follows GENinCode’s recent partnership with the Mexican Association for the Prevention of Atherosclerosis.
“We are delighted to announce this latest distribution agreement with Sohin Genetics to sell CARDIO inCode-Score in Mexico,” said chief executive officer Matthew Walls.
In London, GENinCode shares moved up 5.26% changing hands at 3p, and earlier traded as high as 3.3p.